In this episode of Nothing Ventured, host Aarish Shah welcomes Dr. Uzma Choudry, an expert in deep tech and biotech investing. Uzma shares her extensive experience in developing the European tech bio ecosystem, including her role in managing a portfolio of over one and a half billion pounds at one of Europe's largest funds. The conversation delves into the current state of the life sciences venture market, highlighting the recent debloating of the venture bubble and the withdrawal of generous capital. Uzma explains the unique challenges in biotech, where the focus is primarily on de-risking technology and science rather than immediate revenue scaling. She emphasises the necessity for deep pools of capital in biotech investments and discusses how platform companies can showcase their value through their assets. Tune in for insights on sustainable growth and commercialization in the life sciences sector.

Nothing Ventured

[email protected] (Aarish Shah - EmergeONE)

Uzma Choudry: Building a Unique European BioTech Ecosystem | Episode 57

DEC 19, 202452 MIN
Nothing Ventured

Uzma Choudry: Building a Unique European BioTech Ecosystem | Episode 57

DEC 19, 202452 MIN

Description

In this episode of Nothing Ventured, host Aarish Shah welcomes Dr. Uzma Choudry, an expert in deep tech and biotech investing. Uzma shares her extensive experience in developing the European tech bio ecosystem, including her role in managing a portfolio of over one and a half billion pounds at one of Europe's largest funds. The conversation delves into the current state of the life sciences venture market, highlighting the recent debloating of the venture bubble and the withdrawal of generous capital. Uzma explains the unique challenges in biotech, where the focus is primarily on de-risking technology and science rather than immediate revenue scaling. She emphasises the necessity for deep pools of capital in biotech investments and discusses how platform companies can showcase their value through their assets. Tune in for insights on sustainable growth and commercialization in the life sciences sector.